Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
      Description

      This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in patients with R/R NHL. The Phase 1a stage of the study will explore escalating doses of single-agent KT-413. The Phase 1b stage will be split into 2 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in MYD88 mutant and MYD88 wild-type R/R DLBCL.

      Conditions
      Non Hodgkin LymphomaDiffuse Large B Cell LymphomaDLBCLMYD88 Gene Mutation
      Talk to us
      ACTIVE_NOT_RECRUITING
      Ibrutinib + Venetoclax in Untreated WM
      Description

      This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this study are: * Venetoclax * ibrutinib

      Conditions
      Waldenstrom MacroglobulinemiaMYD88 Gene Mutation
      Talk to us